Christopher Richard Anzalone Sells 51,726 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 51,726 shares of the business’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $69.13, for a total transaction of $3,575,818.38. Following the sale, the chief executive officer directly owned 3,805,926 shares in the company, valued at approximately $263,103,664.38. This trade represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

• On Monday, December 22nd, Christopher Richard Anzalone sold 12,586 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $68.44, for a total value of $861,385.84.
• On Friday, December 19th, Christopher Richard Anzalone sold 13,445 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $67.66, for a total transaction of $909,688.70.
• On Wednesday, December 17th, Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $64.04, for a total transaction of $5,443,400.00.
• On Tuesday, December 16th, Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $62.58, for a total transaction of $3,397,968.84.
• On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $68.85, for a total transaction of $8,950,500.00.

Arrowhead Pharmaceuticals Trading Down 1.3%

Arrowhead Pharmaceuticals stock opened at $66.39 on Thursday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $72.36. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock has a market cap of $9.02 billion, a P/E ratio of -829.77 and a beta of 1.28. The company’s fifty day simple moving average is $53.54 and its 200-day simple moving average is $34.15.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ARWR shares. The Goldman Sachs Group raised their price target on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research note on Thursday, November 20th. Royal Bank Of Canada raised their price objective on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Morgan Stanley lifted their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 26th. Chardan Capital reissued a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. Finally, Piper Sandler raised their price target on shares of Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $61.89.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 3.1% during the 3rd quarter. PNC Financial Services Group Inc. now owns 10,924 shares of the biotechnology company’s stock worth $377,000 after buying an additional 326 shares during the period. State of Wyoming lifted its position in Arrowhead Pharmaceuticals by 5.6% during the 3rd quarter. State of Wyoming now owns 9,519 shares of the biotechnology company’s stock worth $328,000 after acquiring an additional 504 shares during the last quarter. Arizona State Retirement System lifted its position in Arrowhead Pharmaceuticals by 1.9% during the 3rd quarter. Arizona State Retirement System now owns 32,661 shares of the biotechnology company’s stock worth $1,126,000 after acquiring an additional 620 shares during the last quarter. CWM LLC boosted its holdings in Arrowhead Pharmaceuticals by 6.7% during the third quarter. CWM LLC now owns 12,179 shares of the biotechnology company’s stock valued at $420,000 after acquiring an additional 764 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $29,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.